Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: L03 • ACR Convergence 2024
CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus
Kyleigh Brimmer¹, Olivia Antao¹, Daniel Mayer¹, Gina Sanchez¹, Rebecca Francis¹, Htay Htay Kyi², Mary Salim², Boyan Xia², Eugenio Capitle² and Jason Weinstein¹, ¹Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ, ²Division of Allergy, Immunology and Rheumatology, University Hospital, Newark, NJ
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…
Abstract Number: L11 • ACR Convergence 2024
Rheumatology Diagnostics Utilizing Artificial Intelligence (ANA Reader©) for ANA Pattern Identification and Titer Quantification
May Choi¹, Farbod Moghaddam¹, Mohammad Sajadi¹, Ann E. Clarke¹, Sasha Bernatsky², Karen Costenbader³, Irene Chen⁴, Murray Urowitz⁵, John Hanly⁶, Caroline Gordon⁷, Sang-Cheol Bae⁸, Juanita Romero-Diaz⁹, Jorge Sanchez-Guerrero¹⁰, Daniel Wallace¹¹, David Isenberg¹², Anisur Rahman¹³, Joan Merrill¹⁴, Paul Fortin¹⁵, Dafna Gladman¹⁶, Ian Bruce¹⁷, Michelle Petri¹⁸, Ellen Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jönsen²³, Graciela Alarcón²⁴, Ronald Van Vollenhoven²⁵, Cynthia Aranow²⁶, Meggan Mackay²⁶, Guillermo Ruiz-Irastorza²⁷, S. Sam Lim²⁸, Murat Inanç²⁹, Kenneth Kalunian³⁰, Soren Jacobsen³¹, Christine Peschken³², Diane Kamen³³, Anca Askanase³⁴, Marvin Fritzler³⁵ and Mina Aminghafari¹, ¹University of Calgary, Calgary, AB, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ⁴UC Berkeley and UCSF, Berkeley, CA, ⁵Self employed, Toronto, ON, Canada, ⁶Dalhousie University, Halifax, NS, Canada, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸Hanyang University Medical Center, Seoul, South Korea, ⁹The National Institute of Medical Sciences and Nutrition, Mexico City, Mexico, ¹⁰Krembil Research Institute, Toronto, ON, Canada, ¹¹Cedars Sinai Medical Center, Studio City, CA, ¹²Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, ¹³University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Centre ARThrite - CHU de Québec - UniversitéLaval, Quebec, QC, Canada, ¹⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁷Queen's University Belfast, Belfast, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, New York, NY, ²⁰UNC physician network, Chapel Hill, NC, ²¹Northwestern University, Chicago, IL, ²²Allegheny Health Network, Pittsburgh, PA, ²³Lund University, Lund, Sweden, ²⁴The University of Alabama at Birmingham, Oakland, CA, ²⁵Amsterdam UMC, Amsterdam, Netherlands, ²⁶Feinstein Institutes for Medical Research, New York, NY, ²⁷Biobizkaia Health Research Institute, Bilbao, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Istanbul University, Istanbul, Turkey, ³⁰UC San Diego, La Jolla, CA, ³¹Rigshospitalet, Copenhagen, Denmark, ³²University of Manitoba, Winnipeg, MB, Canada, ³³Medical University of South Carolina, Johns Island, SC, ³⁴Columbia University Medical Center, New York, NY, ³⁵Mitogen Diagnostics Corp, Calgary, AB, Canada
Background/Purpose: Antinuclear antibody (ANA) immunofluorescence (IFA) patterns and titers are a key part of rheumatology diagnostics, however, there is considerable intra- and inter-laboratory variability with…
Abstract Number: L12 • ACR Convergence 2024
A-319, a CD3 X CD19 T Cell Engager (TCE), for the Treatment of Severe/Refractory SLE: Early Evidence of Rapid Reset of Disease-Specific Autoimmunity
Chunli Mei¹, Xin Guan¹, Bin Wu², Mengjiao Li¹, Xiaojing Liu¹, Xi Chen¹, You Song¹, Weiwei Wang¹, Cheng Wang¹, Huiling Mei¹, Xiaoru Duan¹, Lijuan Jiang¹, Wenlin Qiu¹, Likai Yu¹, Yuhong Liu¹, Xing Zhao³, Xuanfan Zhong³, Shengjie Xue³, Wuzhong Shen³, Ying Tan³, Guojian Yu³, Guiyun Tu³, Hanyang Chen³, Amy Sun³, Xiaoqiang Yan³, Anbing Huang¹, Rong Du¹ and Qiubai Li¹, ¹Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ²Department of Rheumatology and Immunology of the First People’s Hospital of Jingzhou, Jingzhou, China, ³ITabMed Ltd. Changchun, Shanghai, China
Background/Purpose: CD19 CAR T treatment has demonstrated clinical benefits to patients with severe/refractory systemic lupus erythematosus (SLE), possibly due to resetting autoimmunity. A-319, a highly…
Abstract Number: L13 • ACR Convergence 2024
Anifrolumab Long-Term Treatment Is More Effective Against Organ Damage Than Standard of Care Alone: Results from an External Control Arm Study on Organ Damage in Phase 3 Clinical Trials and the University of Toronto Lupus Clinic Cohort
Zahi Touma¹, Ian Bruce², Richard A. Furie³, Eric Morand⁴, Raj Tummala⁵, Shelly Chandran⁶, Gabriel Abreu⁷, Jacob Knagenhjelm⁷, Kellyn Arnold⁸, Hopin Lee⁸, Eleanor Ralphs⁸, Danuta Kielar⁹, Aleksander Bedenkov⁹ and Miina Waratani⁹, ¹Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ²Queen's University Belfast, Belfast, United Kingdom, ³Northwell Health, Manhasset, NY, ⁴Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁶Astrazeneca, Mississauga, ON, Canada, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁸IQVIA, London, United Kingdom, ⁹Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: In SLE, persistent disease activity, disease flares and long-term glucocorticoid (GC) use all contribute to organ damage accrual. The effects of novel therapies on…
Abstract Number: L16 • ACR Convergence 2024
Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial
Megan Clowse¹, David Isenberg², Joan Merrill³, Thomas Dörner⁴, Michelle Petri⁵, Edward Vital⁶, Eric Morand⁷, Teri Jimenez⁸, Stephen Brookes⁹, Janine Gaiha-Rohrbach¹⁰, Christophe Martin¹¹, Annette Nelde¹² and Christian Stach¹³, ¹Division of Rheumatology and Immunology, Duke University, Durham, NC, ²Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁸UCB, Raleigh, NC, ⁹Biogen, Maidenhead, United Kingdom, ¹⁰Biogen, Cambridge, MA, ¹¹UCB, Slough, United Kingdom, ¹²Biogen, Baar, Switzerland, ¹³UCB, Monheim am Rhein, Germany
Background/Purpose: Dapirolizumab pegol (DZP) is a novel, polyethylene glycol (PEG)-conjugated antigen-binding (Fab') fragment, lacking an Fc domain, that inhibits CD40L signaling. By binding to CD40L,…
Abstract Number: L17 • ACR Convergence 2024
Allogenic CD19 CAR NK Cells Therapy in Refractory Systemic Lupus Erythematosus: An Open-label, Single Arm, Prospective and Interventional Clinical Trial
Yiyi Yu¹, Ruina Kong¹, Xia Xu¹, Suxuan Liu¹, Qian Chen¹, Xiaofang Li², Ming Sun², Jianmin Yang¹, Dongbao Zhao¹ and Jie Gao¹, ¹Changhai Hospital, Shanghai, China, ²Rui Therapeutics, Nanjing, China
Background/Purpose: Treatment of systemic lupus erythematosus (SLE) typically necessitates long-term immunosuppression with hormones, immunosuppressants and biologics. CD19-targeting chimeric antigen receptor (CAR) T cells have shown excellent…
Abstract Number: 0090 • ACR Convergence 2024
Parenchymal and Hematopoietic IFNγ Signaling Exhibits Dichotomous Effects in Murine Lupus
Minjung Kim¹, Anthony Marinov², Haylee Cosgrove³, Xiaoyan Gong³, Mark Shlomchik³ and Jeremy Tilstra³, ¹University of Illinois College of Medicine at Chicago, Chicago, IL, ²University of Pittsburgh, Homestead, PA, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Lupus nephritis is the most common life-threatening end-organ complication of SLE, and response rates to current interventions remain poor. Notably, PD-L1 and other interferon-responsive…
Abstract Number: 0166 • ACR Convergence 2024
Limitations in Activities of Daily Living Among Individuals with SLE
Laura Plantinga¹, Jinoos Yazdany², Courtney Hoge³, Charmayne M. Dunlop-Thomas⁴ and Patti Katz⁵, ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³Emory University, Atlanta, GA, ⁴Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ⁵UCSF, San Rafael, CA
Background/Purpose: A better understanding of the capacity of individuals with SLE to perform routine daily life tasks is needed to effectively support the independence and…
Abstract Number: 0190 • ACR Convergence 2024
Socioeconomic Disparities in Functional Status by Neighborhood Deprivation in a National Sample of Patients with Systemic Lupus Erythematosus
Baljeet Rai¹, Jessica Fitzpatrick², Jing Li³, Gabriela Schmajuk⁴ and Jinoos Yazdany⁵, ¹University of California, San Francisco, Modesto, CA, ²University California, San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵University of California San Francisco, San Francisco, CA
Background/Purpose: Individuals with SLE can experience significant declines in functional status (FS). The ACR has recently identified physical function as a high-priority domain in SLE…
Abstract Number: 0351 • ACR Convergence 2024
Empowering Lupus Communities: Evaluating a National Peer Support Program for Lupus Teen, Young Adult Patients and Their Families
Giselle Rodriguez, LCSW¹, Priscilla Calvache¹, Lillian Mendez², Kimberly Cabrera¹, Roberta Horton¹, Lisa Imundo³ and Jillian Rose-Smith¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Carteret, NJ, ³New York Presbyterian Hospital - Columbia Campus, New York, NY
Background/Purpose: Research shows that peer support groups effectively provide emotional support, enhance knowledge, & improve coping for chronic illnesses. An evaluation of a bilingual hospital…
Abstract Number: 0441 • ACR Convergence 2024
A Qualitative Improvement Project to Incorporate the Mycophenolate Risk Evaluation and Mitigation Strategies in an Academic Lupus Clinic
Dahima Cintron¹, Jennifer Rogers², Rebecca Sadun¹, Mithu Maheswaranathan³, Kai Sun¹, Jayanth Doss¹, Lisa Criscione-Schreiber³ and Megan Clowse⁴, ¹Duke University, Durham, NC, ²Duke, Durham, NC, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Mycophenolate Mofetil/Mycophenolic acid (MMF) is an immunosuppressant used to treat SLE. Due to the teratogenic effects of MMF, the FDA recommended universal risk evaluation…
Abstract Number: 0617 • ACR Convergence 2024
Hereditary C1q Deficiency Is Associated with Type 1 Interferon-pathway Activation and a High Risk of Central Nervous System Inflammation
Clément triaille¹, Neha Mohan Rao², Gillian Rice³, Luis Seabra⁴, Sutherland Fraser⁵, Vincent Bondet⁶, Darragh duffy⁶, Andrew Gennery⁷, Benjamin Fournier⁸, Brigitte Bader-Meunier⁹, Christopher Troedson¹⁰, Gavin CLeary¹¹, Helena Buso¹², Jacqueline Dalby-Payne¹³, Ranade Prajakta¹⁴, Katrien Jansen¹⁵, Lien De Somer¹⁶, Marie-Louise Fremond¹⁷, Pimple Pallavi¹⁴, Melanie Wong¹⁸, Russel Dale¹⁰, Carine Wouters¹⁶, PIERRE QUARTIER¹⁹, Raju Khubchandani²⁰ and Yanick Crow⁵, ¹Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, Brussels, Belgium, ²NH SRCC hospital, Department of Pediatric Rheumatology, Mumbai, Maharashtra, India, Mumbai, ³Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, ⁴Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Paris, France, Paris, France, ⁵MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom, Edinburgh, United Kingdom, ⁶Translational Immunology Unit, Institut Pasteur, Université Paris-Cité, Paris, France, Paris, France, ⁷: Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, Newcastle, United Kingdom, ⁸Paediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital, APHP Centre, Université Paris-Cité, Paris, France, Paris, France, ⁹Necker Hospital, Assistance Publique Hopitaux de Paris, Paris, France, ¹⁰T. Y. Nelson Department of Neurology and Neurosurgery, Children's Hospital at Westmead, Westmead, New South Wales, and University of Sydney, Australia, Sydney, Australia, ¹¹: Paediatric Rheumatology, Alder Hey Children's Hospital, Liverpool, United Kingdom, Liverpool, United Kingdom, ¹²Department of Medicine - DIMED, University of Padova, Padova, Italy, Padova, Italy, ¹³Specialty of Child and Adolescent Health, Faculty of Medicine, The University of Sydney, Australia, Sydney, Australia, ¹⁴NH SRCC hospital, Department of Pediatric Rheumatology, Mumbai, Maharashtra, India, Mumbai, India, ¹⁵Division of Pediatric Neurology, Department of Pediatrics, University Hospitals Leuven, Belgium, Leuven, Belgium, ¹⁶Division of Pediatric Rheumatology, Department of Pediatrics, University Hospitals Leuven, Belgium, Leuven, Belgium, ¹⁷Paediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital, APHP Centre, Université Paris-Cité, Paris, France, Paris, United Kingdom, ¹⁸Department of Allergy and Immunology, Children's Hospital at Westmead, Westmead, Australia, Westmead, Australia, ¹⁹Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France, ²⁰SRCC Childrens Hospital, Mumbai, India
Background/Purpose: To report on the largest cohort of C1Q deficient (C1QDef ) patients; to investigate the activation of Type 1 interferon pathway in the blood…
Abstract Number: 0635 • ACR Convergence 2024
Medical Record Natural Language Processing and Patient Biometric and Self-Reported Measures Inform an Artificial Intelligence Augmented Remote Care Management Strategy for Lupus Patients
Gerald Lushington¹, Bruce Wang², Mohan Purushothaman³, Melissa Munroe⁴, Vijay R. Nadipelli⁵, Bernard Rubin², Jessica Crawley², Beth Valashinas⁶, Reshma Khan⁷, Anil Warrier⁸, Joseph Huffstutter⁹, Jennifer Murphy¹⁰, Lizeth Santamaria², Sneha Nair², Georg Armstrong², Sandeep Nair², Daniele DeFreese³, Adrian Holloway³, Arif Sorathia², Brett Adelman², Fabricio Pautasso² and Eldon Jupe³, ¹Progentec Diagnostics, Inc, Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OK, ³Progentec Diagnostics, Inc., Oklahoma City, ⁴Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ⁵GSK, Medical Evidence Generation, Philadelphia, PA, ⁶Physicians Alliance of Connecticut, Milford, CT, ⁷Palm Beach Rheumatology and Wellness Center, Jupiter, FL, ⁸Millennium Rheumatology, Conroe, TX, ⁹Arthritis Associates PLLC, Signal Mountain, TN, ¹⁰Articularis Healthcare, Summerville, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is one of several rheumatologic disorders that presents frequent healthcare challenges, particularly for socioeconomic and geographically disadvantaged patients. Due to…
Abstract Number: 0654 • ACR Convergence 2024
Corneal Confocal Microscopy: An Ophthalmic Imaging Biomarker for Small Fiber Neuropathy in Systemic Lupus Erythematosus
Miral Gharib¹, Georgios Baloglu Baloglu², Soha Osman¹, Rayaz A.Malik³ and Samar Alemadi⁴, ¹hamad medical corporation, Doha, Qatar, ²Weill Cornell Medicine , Qatar, doha, ³Weill Cornell Medicine , Qatar, doha, Qatar, ⁴Hamad medical corporation, Doha, Qatar
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disease with frequent neuropsychiatric symptoms associated with poor outcomes. Small fiber neuropathy can cause intolerable…
Abstract Number: 0672 • ACR Convergence 2024
Pharmacokinetics (PK), Effectiveness and Safety of Open-label (OL) Tofacitinib for the Treatment of Moderate to Severe Skin Involvement in Young Adults with SLE
Ivanna Romankevych¹, Nora Singer², Kaliyani Marathe³, Angela Merritt¹, Ekemini Ogbu⁴, Chen Chen⁵, Megan Quinlan-Waters¹, Kathleen Pelletier⁶, Haihong Shi⁶, Xiaoxing Wang⁶, Bin Huang⁷ and hermine brunner⁴, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ³Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, DC, ⁴Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cin, OH, ⁶Pfizer Inc, Groton, CT, ⁷Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH
Background/Purpose: Many cytokines implicated in lupus pathogenesis depend on JAK signaling to exert their intracellular action. Tofacitinib (TOFA) inhibits signaling by cytokine receptors associated with…

1
2
3
…
150
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].